

U.S. Appl. Ser. No. 09/857,000
Final Office action mailed March 28, 2007
Amendment after Final dated August 28, 2007

Amendments to the Specification:

Please replace the Table I at page 16 with the following:

Table I

Compound	
No. 1 (Doxo-SynB1) (SEQ ID NO: 11)	Doxo-CO-(CH ₂) ₂ -CO-RGGRLSYSRRRFSTSTGR
No. 2 (Doxo-SMP-3MP- peptide with amino acids in d form) (SEQ ID NO: 13)	Doxo-SMP-3MP-rqikiwfmrrmkwkk

U.S. Appl. Ser. No. 09/857,000
Final Office action mailed March 28, 2007
Amendment after Final dated August 28, 2007

Amendments to the Specification (Continued):

Please replace the Table VII at page 29 with the following:

Table VII

Compound	
3: dalargine	Y- (D) A-GFLR
4: dal-SynB1 (SEQ ID NO: 11)	Y- (D) A-GFLR-S-S-RGGRLSYSRRRFSTSTGR

U.S. Appl. Ser. No. 09/857,000
Final Office action mailed March 28, 2007
Amendment after Final dated August 28, 2007

Amendments to the Specification (Continued):

Please replace the Table VIII at page 31 with the following:

Table VIII

Compound	
Doxo	doxorubicin
No. 5: doxo-SynB3 (SEQ ID NO: 12)	Doxo-CO-(CH ₂) ₂ -CO-RRLSYSRRRF

U.S. Appl. Ser. No. 09/857,000
Final Office action mailed March 28, 2007
Amendment after Final dated August 28, 2007

Amendments to the Specification (Continued):

Please replace the Table IX at page 33 with the following:

Table IX

Compound	
PNC	Benzylpenicillin
<u>No. 6</u> : PNC-SynB1 (SEQ ID NO: 11)	PNC-linker-RGGRLSYSRRRFSTSTGR